SRPT Sarepta Therapeutics, Inc.
Healthcare$16.80-0.94%ClosedMarket Cap: $1.77B
As of 2026-05-25
Valuation
P/E (TTM)
—
PEG
—
P/B
1.17
P/S
0.81
EV/EBITDA
18.77
DCF Value
$-1,274.69
FCF Yield
6.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
62.4%
Operating Margin
-1.9%
Net Margin
3.0%
ROE
4.9%
ROA
2.0%
ROIC
-1.5%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $730.8M | 83.7% | $358.4M | $331.0M | $— | — |
| Q4 null | $442.9M | 10.0% | $-411.6M | $-282.8M | $— | — |
| FY null | $2.20B | 59.9% | $-657.8M | $-713.4M | $— | — |
| Q3 null | $399.4M | 62.2% | $-103.4M | $-179.9M | $— | — |
| Q2 null | $611.1M | 75.0% | $115.6M | $196.9M | $— | — |
| Q1 null | $744.9M | 81.5% | $-300.4M | $-447.5M | $— | — |
| Q4 null | $658.4M | 79.9% | $161.7M | $159.0M | $— | — |
| FY null | $1.90B | 83.2% | $218.1M | $235.2M | $— | — |
| Q3 null | $467.2M | 80.4% | $22.2M | $33.6M | $— | — |
| Q2 null | $362.9M | 87.7% | $-701.0K | $6.5M | $— | — |
| Q1 null | $413.5M | 87.8% | $34.9M | $36.1M | $— | — |
| Q4 2023 | $396.8M | 88.9% | $24.6M | $45.7M | $0.43 | — |